Revolutionizing Health: Low Dose Naltrexone and Therapeutic Plasma Exchange - Dr Pamela Smith

Dr. Yusaf (PJ) Saleeby shares insights from his practice in 2025 regarding Low Dose Naltrexone (LDN). He discusses patient sensitivity, optimal starting doses, and LDN's efficacy for various conditions including Lyme, cancer, and autoimmune diseases. The conversation also delves into Mast Cell Activation Syndrome (MCAS) and the critical role of informed clinicians in its management.

Low dose naltrexone (LDN) offers potential benefits for various health issues. A Missie from the US shares her personal experience with LDN, highlighting her battles with chronic pain, autoimmune diseases, and a blood disorder. After initial scepticism, she notices significant health improvements, including better sleep and reduced pain. LDN helps reverse organ damage and improve her blood condition, emphasising the need for patience and openness to its benefits.

Pharmacist Dr. James Blackburn shares his journey in pharmacy and the significance of compounding. He discusses low-dose naltrexone (LDN) and its benefits for autoimmune diseases, mental health, and women's health. Insights on compounding practices, quality, and personal experiences with fertility and mental health challenges are highlighted. Dr. Blackburn emphasizes the importance of proper testing and lifestyle's impact on health, addressing the community's need for effective treatments.

DescriptionExplore the profound impact of music therapy with Professor Lee Anna Rasar on the LDN Radio Show. Discover how adapted songs aid anger management, how harmonica playing enhances respiratory function, and how melodic intonation therapy assists stroke patients. Learn about music's role in sleep induction, dementia care, and Parkinson's gait training, showcasing its neuroscience-based approach.Book for the Live Zoom webinar, $20 including the recordingWith Lee Anna Rasar, Professor of Music Education/Therapy,titled “Dancing in the Rain: Music to Complement LDN.”for medical professionals and patients28th April at 11:00 a.m. Central Time (5:00 p.m. UK Time).1-hour presentation followed by a 1-hour live Q&Aregister at https://linktr.ee/ldnrt

Low dose naltrexone (LDN) shows promise in treating autoimmune diseases and cancers. Dr. Stephanie Werner shares insights on LDN's effectiveness in managing inflammation and enhancing patient outcomes, particularly in women's health issues like polycystic ovary syndrome and pregnancy challenges. The importance of diet and avoiding inflammatory foods is discussed, along with personal responsibility in healthcare and LDN's potential in managing chronic conditions.

Low-dose naltrexone (LDN) is highlighted as a supportive treatment in oncology, enhancing other therapies rather than acting alone. It helps regulate the immune system, calms microglia, and alleviates symptoms like pain and fatigue. LDN's low toxicity and potential to improve quality of life are emphasized, along with its evolving role in cancer therapies and immune modulation.

Low-dose naltrexone (LDN) is discussed as a treatment for chronic illnesses, focusing on its effectiveness and dosing protocols. Experts highlight the importance of collaboration among healthcare providers and the need for more research and awareness. They address misconceptions, potential insurance coverage, and share patient experiences, emphasizing personalized care in managing chronic conditions. The show invites further inquiries from the audience.

LDN treatment involves specific dosing strategies and patient experiences, particularly for conditions like multiple sclerosis and restless leg syndrome. Timing of medication is crucial, and the discussion highlights the rising prevalence of autism, potential links to environmental toxins, and dietary influences. Families face challenges in managing these conditions, emphasizing the need for ongoing communication between practitioners and patients as understanding of LDN's applications evolves.

Dr. Pamela Smith explores the benefits of low dose naltrexone (LDN) and therapeutic plasma exchange (TPE) for treating toxins and autoimmune diseases. She discusses the rising toxicity in patients and how combining TPE with LDN and nutrients can enhance health outcomes. The importance of personalized treatment plans and the role of inflammation in chronic diseases are highlighted, along with insights on managing medication tolerance and the need for ongoing research.

Dr. Phil Boyle explains how low-dose naltrexone can effectively treat infertility and recurrent miscarriage. He outlines the clinical criteria for its use and shares patient experiences. Maintaining treatment during pregnancy is crucial for better outcomes. The discussion also covers naltrexone's potential benefits for postpartum depression and the significance of endorphin levels in health. Dr. Boyle concludes with a mention of a new publication in restorative reproductive medicine.